“Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022” report highlights: Categorization of Cancer Immunotherapy Market Aspects of Cancer Immunotherapy Clinical Trials and Development Insight Global Cancer Immunotherapy Pipeline Overview Marketed Cancer Immunotherapy by Class Global Cancer Immunotherapy Market Future Prospects Competitive Analysis

1. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 1
“Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022” report gives
comprehensive insight on clinical and non-clinical developments in the field of cancer
immunotherapy. According to report, cancer immunotherapy has emerged as the new growth
frontier for the pharmaceutical companies involved in the clinical research and development
of cancer drugs and therapeutics. Currently there are more than 2000 cancer
immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in
preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal
antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially
available in the market.
Pharmaceutical companies are actively engaged in research and development of cancer
immunotherapies because of large unmet medical necessities. Investigators are trying to
come forth with innovative cancer immunotherapeutic products having high safety and
efficacy profiles which are not offered by conventional therapeutics. Higher investments in
research and development segment could significantly increase the drug discovery rates
which will alleviate the medical condition of cancer patients. Simultaneously, technological
advancements are being made due to which development of worthy candidates with high
commercialization and pharmacological potential is expected to increase in coming years.
Investigators are trying to decipher underlying principle of cancer progression and
proliferation. Different cancer indications have different requirements for developing
effective therapeutics due to which identification of these factors have become important.
This knowledge would be used for developing innovative cancer immunotherapies for various
malignancies.
Cancer immunotherapeutics based on these discoveries would pave path for market
introduction of highly effective therapeutics. Some progress has been made which could be
noticed by observing plethora of cancer immunotherapeutics available for different cancer
indications. Their clinical pipeline is also developing rapidly and various products are at
different stages of clinical trials. They are expected to offer severe competition to presently
available cancer therapeutics with modest pharmacological efficacy.
Cancer immunotherapies have been used for limited number of malignancies as compared to
other drug categories. Mostly hematological malignancies like follicular lymphoma, chronic
lymphocytic leukemia and diffuse large B cell non-Hodgkin’s lymphoma have remained the

2. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 2
focal point. Other cancer indications like melanoma, NSCLC, prostate cancer and RCC have
also got cancer immunotherapeutics.
Most like, cancer therapeutics in clinical trials would be able to present positive data that
will allow them to easily enter in global market. Cancer incidences are escalating rapidly and
cancer immuno therapeutics seems to play an important role in offering better medical care
to patients. Some of them have received FDA’s accelerated approval and breakthrough
therapy designation due to their superior pharmacological benefits. It is expected that similar
progress would be shown by cancer immunotherapeutics under development for different
malignancies.
“Global Cancer Immunotherapy Market and Clinical Trials Outlook
2022” report highlights:
 Categorization of Cancer Immunotherapy
 Market Aspects of Cancer Immunotherapy
 Clinical Trials and Development Insight
 Global Cancer Immunotherapy Pipeline Overview
 Marketed Cancer Immunotherapy by Class
 Global Cancer Immunotherapy Market Future Prospects
 Competitive Analysis
For Report Sample Contact: neeraj@kuickresearch.com

3. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 3
Table of Contents
1. Immunotherapy: Mending Cancer Regimens
1.1 Preface to Cancer Immunotherapy
1.2 Evolution of Cancer Immunotherapy
2. Categorization of Cancer Immunotherapy
2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors
3. Fundamentals of Cancer Vaccines
3.1 Prologue of Cancer Vaccines
3.2 Cancer Vaccines in Immunotherapy
3.3 Commercial Aspects of Cancer Vaccines
4. New Era of Monoclonal Antibodies
4.1 Rudiments of Monoclonal Antibodies
4.2 Advents of Monoclonal Antibodies
4.3 Commercial Aspects of Monoclonal Antibodies
5. Trails of T-Cell Therapies
5.1 Adoptive Cell Transfer Technology
5.2 Strategies of Adoptive Cell Transfer
5.3 Commercial Aspects of Adoptive Cell Therapy
6. Aspects of Immune Checkpoint Inhibitors
6.1 Prelude to Immune Checkpoint Inhibitors

4. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 4
6.2 Implications of Immunecheck Point Inhibitors
6.3 Commercial Aspects of Immune Checkpoint Inhibitors
7. Immunomodulators in Cancer Immunotherapy
7.1 Perspective of Immunomodulators
7.2 Clinical Aspects of Immunomodulators
7.3 Commercial Aspects of Immunomodulators
8. Oncolytic Viral Immunotherapy
8.1 Concept to Oncolytic Viruses
8.2 Potential Approaches of Oncolytic Viruses
8.3 Commercial Aspects of Oncolytic Viruses
9. Cytokines in Cancer Immunotherapy
9.1 Fundamentals of Cytokines
9.2 Classification of Cytokines
9.3 Commercial Aspects of Cytokines
10. Interferons in Immunotherapy
10.1 Potentials of Interferons
10.2 Classification of Interferons
10.3 Clinical Applications of Interferons
11. Interleukins in Immunotherapy
11.1 Potentials of Interleukins
11.2 Clinical Applications of Interleukins
12. GM-CSF in Immunotherapy
12.1 Potentials of GM-CSF
12.2 Clinical Applications of GM-CSF
13. Global Economic Evaluations
13.1 Economic Aspects of Cancer Immunotherapy

5. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 5
13.2 Cancer Immunotherapy Cost by Product
14. Market Aspects of Cancer Immunotherapy
14.1 Current Market Trends
14.2 Cancer Immunotherapy Pipeline Overview
15. Global Cancer Immunotherapy Market Dynamics
15.1 Favorable Market Parameters
15.2 Commercialization Challenges
16. Marketed Cancer Cell Therapies Drugs
16.1 Sipuleucel-T (Provenge®)
16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®)
17. Marketed Cancer Cytokines Drugs
17.1 Aldesleukin (Proleukin®)
17.2 Denileukin Diftitox (ONTAK®)
17.3 Interferon Alpha (Multiferon®)
17.4 Interferon Alpha-2a (Roferon-A®)
17.5 Interferon Alpha-2a (Veldona®)
17.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
17.7 Interferon Alpha-2b(Intron® A)
17.8 Interferon Alpha-2b Biosimilar(Bioferon™)
17.9 Interferon Alpha-2b Biosimilar (Intalfa®)
17.10 Interferon Alpha-2b Biosimilar
17.11 Interferon-Alpha-n3 (Alferon N®)
17.12 Interferon-Beta-1b (Feron®)
17.13 Interferon-Gamma (Ogamma®)
17.14 Interleukin-2 Biosimilar (Ilcass)
17.15 Teceleukin (Imunace™)

6. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 6
18. Marketed Cancer Vaccines
18.1 Bladder Cancer Vaccine (PACIS®)
18.2 Bladder Cancer Vaccine
18.3 BV NSCLC 001
18.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
18.7 Melanoma Vaccine (MVax®)
18.8 Melanoma Vaccine (Melacine®)
18.9 Racotumomab (Vaxira®)
18.10 Sipuleucel-T (Provenge®)
18.11 Tertomotide (LucaVax)
18.12 Vitespen (Oncophage®)
19. Marketed Cancer Monoclonal Antibodies
19.1 Bevacizumab
19.2 Trastuzumab Emtansine
19.3 Trastuzumab Subcutaneous
19.4 Brentuximab Vedotin
19.5 Catumaxomab
19.6 Ipilimumab
19.7 Nivolumab
19.8 Pembrolizumab
19.9 Pertuzumab
19.10 Rituximab
19.11 Trastuzumab

7. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 7
20. Global Cancer Immunotherapy Market Future Prospects
21. Competitive L&scape
21.1 Abbvie
21.2 Advaxis
21.3 Altor BioScience
21.4 Amgen
21.5 Biogen Idec
21.6 Biogenomics
21.7 Celldex Therapeutics
21.8 Dendreon Corporation
21.9 Eli Lilly
21.10 Expression Genetics
21.11 Galena Biopharma
21.12 Genmab
21.13 Gilead Sciences
21.14 GlaxoSmithKline
21.15 ImmunoCellular Therapeutics
21.16 ImmunoGen
21.17 Inovio Pharmaceuticals
21.18 IRX Therapeutics
21.19 Merck
21.20 NeoStem Oncology
21.21 NewLink Genetics
21.22 Northwest Biotherapeutics
21.23 Novartis

8. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 8
21.24 Peregrine Pharmaceuticals
21.25 Pfizer
21.26 Philogen
21.27 Regulon
21.28 Roche
21.29 Seattle Genetics
21.30 ZymoGenetics
List of Figures
Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
Figure 1-3: Potential Benefits of Cancer Immunotherapies
Figure 2-1: Classification of Cancer Immunotherapies
Figure 2-2: Categorization of Specific Immunotherapy
Figure 2-3: Non-Specific Cancer Immunotherapies
Figure 3-1: Categorization & Function of Cancer Vaccines
Figure 3-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
Figure 3-3: Global Cancer Vaccines Market (US$ Billion), 2016-2022
Figure 4-1: Process of Manufacturing of Monoclonal Antibody
Figure 4-2: Principles of Monoclonal Antibodies
Figure 4-3: Evolution of Monoclonal Antibody over Generations
Figure 4-4: Classification of Monoclonal Antibodies
Figure 4-5: Representation of Mechanism of Alemtuzumab
Figure 4-6: Representation of Mechanism of Ibritumomab Tiuxetan
Figure 4-7: Representation of Mechanism of Blinatumomab
Figure 4-8: Global Market for Cancer Monoclonal Antibodies (US$ Billion), 2016-2022
Figure 5-1: Benefit of Adoptive Cell Transfer Immunotherapy
Figure 5-2: Systematic Representation of Adoptive T-Cell Therapies
Figure 5-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
Figure 5-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
Figure 5-5: Mechanism of CAR Modified T-Cells
Figure 5-6: Genetically Engineered TCR for Cancer Immunotherapy
Figure 5-7: Global Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2016-2022
Figure 6-1: Benefits of Immune Checkpoint Inhibitors
Figure 6-2: Implication of Adaptive Immune Resistance Mechanism
Figure 6-3: Mechanism of Ipilimumab
Figure 6-4: Layout of Mechanism of Nivolumab
Figure 6-5: Mechanism of Pembrolizumab
Figure 6-6: Global - Immune Check Point Inhibitors Market (US$ Billion), 2016-2022

9. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 9
Figure 7-1: Functions of Immunomodulators
Figure 7-2: Benefits of Immunomodulators
Figure 7-3: Layout of the Challenges of Immunomodulators
Figure 7-4: Properties of Thalidomide
Figure 7-5: Mechanism of Lenalidomide In Vivo
Figure 7-6: Mechanism of Lenalidomide in Vitro
Figure 7-7: Mechanism of Pomalidomide
Figure 7-8: The Global Market for Immunomodulators for All Indications (US$ Billion), 2016-
2022
Figure 8-1: Demonstration of Categorization of Oncolytic Viruses
Figure 8-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 8-3: The Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2016-2022
Figure 9-1: Layout of Functions Performed by Cytokine
Figure 9-2: Benefits of Cytokines in Cancer Immunotherapy
Figure 9-3: Classification of Cytokine Receptor Family
Figure 9-4: Percentage Share of the Cancer Immunotherapies by the Technology
Figure 10-1: Layout of Functions of Interferon
Figure 10-2: Classification of Interferons on the Basis of Types of Genes
Figure 10-3: General Mechanism of Interferons
Figure 10-4: Mechanism of Interferon Alfa-n3
Figure 10-5: Aspects of Peginterferon Alfa-2a
Figure 10-6: Applications of Interferon Beta 1a
Figure 10-7: Potentials of Interferon Alfa-2b
Figure 11-1: Functions of Interleukin
Figure 11-2: Potentials of Interleukins in Cancer Immunotherapy
Figure 11-3: Clinical Potentials of Proleukin
Figure 11-4: Clinical Potentials of Denileukin Diftitox
Figure 12-1: Potential Applications of GM-CSF
Figure 12-2: Mechanism of Sargramostim
Figure 13-1: Expected Cancer Treatment Cost (US$ Billion), 2016-2022
Figure 13-2: Comparative Analysis of Available Cancer Treatments
Figure 13-3: Major Approved Immunotherapeutic Drugs
Figure 13-4: Annual per Patient Drug Expenditure of Immunotherapy
Figure 14-1: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022
Figure 14-2: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2017 - 2022
Figure 14-3: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-4: Global - Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase
(%), 2017 -2022
Figure 14-5: Global - Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase
(Number), 2017 -2022
Figure 14-6: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-7: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2017
-2022
Figure 14-8: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-9: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-10: Global - Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by
Phase (%), 2017 -2022
Figure 14-11: Global - Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by
Phase (Number), 2017 - 2022
Figure 14-12: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2017 - 2022

10. Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022
For sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 10
Figure 14-13: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2017 -
2022
Figure 15-1: Favorable Cancer Immunotherapy Market Parameters
Figure 15-2: Cancer Immunotherapy Commercialization Challenges
Figure 21-1: Advaxis Clinical Pipeline
Figure 21-2: Celldex Therapeutics Clinical Pipeline
Figure 21-3: Expression Genetics Clinical Pipeline
Figure 21-4: Galena Biopharma Clinical Pipeline
Figure 21-5: ImmunoCellular Therapeutics Clinical Pipeline
Figure 21-6: ImmunoGen Clinical Pipeline
Figure 21-7: Inovio Pharmaceuticals Clinical Pipeline
Figure 21-8: NewLink Genetics Corporation Clinical Pipeline
Figure 21-9: Northwest Biotherapeutics Clinical Pipeline
Figure 21-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 21-11: Philogen Clinical Pipeline
Figure 21-12: Seattle Genetics Clinical Pipeline
Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
Table 6-1: Illustration of Some Important Checkpoint Inhibitors
Table 9-1: Few Important Immunocytokines under Clinical Development
Table 9-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
Table 14-1: Few Commercially Important PD-1 Drugs
For Report Sample Contact: neeraj@kuickresearch.com